Patents Assigned to SVC
-
Patent number: 12172038Abstract: Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.Type: GrantFiled: March 31, 2023Date of Patent: December 24, 2024Assignees: AbCellera Biologics Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.Inventors: Kathryn Westendorf, Stefanie Zentelis, Krithika Muthuraman, Kevin Jepson, Ester Falconer, John Mascola, Barney Graham, Kizzmekia Corbett, Julie Ledgerwood, Lingshu Wang, Olubukola Abiona, Wei Shi, Wing-pui Kong, Yi Zhang, Bryan Edward Jones, Denisa Foster, Julian Davies, Qing Chai, Christopher Carl Frye, Ganapathy Gopalrathnam, Jörg Hendle, John Michael Sauder, Jeffrey Streetman Boyles, Anna Pustilnik
-
Publication number: 20240150438Abstract: Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.Type: ApplicationFiled: March 31, 2023Publication date: May 9, 2024Applicants: AbCellera Biologics Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.Inventors: Kathryn WESTENDORF, Stefanie ZENTELIS, Krithika MUTHURAMAN, Kevin JEPSON, Ester FALCONER, John MASCOLA, Barney GRAHAM, Kizzmekia CORBETT, Julie LEDGERWOOD, Lingshu WANG, Olubukola ABIONA, Wei SHI, Wing-pui KONG, Yi ZHANG, Bryan Edward JONES, Denisa FOSTER, Julian DAVIES, Qing CHAI, Christopher Carl FRYE, Ganapathy GOPALRATHNAM, Jörg HENDLE, John Michael SAUDER, Jeffrey Streetman BOYLES, Anna PUSTILNIK
-
Publication number: 20220356229Abstract: Antibodies that bind SARS-CoV Spike protein, SARS-CoV-2 Spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.Type: ApplicationFiled: March 4, 2021Publication date: November 10, 2022Applicants: AbCellera Biologics Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.Inventors: Kathryn WESTENDORF, Stefanie ZENTELIS, Krithika MUTHURAMAN, Kevin JEPSON, Ester FALCONER, John MASCOLA, Barney GRAHAM, Kizzmekia CORBETT, Julie LEDGERWOOD, Lingshu WANG, Olubukola ABIONA, Wei SHI, Wing-pui KONG, Yi ZHANG, Bryan Edward JONES, Denisa FOSTER, Julian DAVIES, Qing CHAI, Christopher Carl FRYE, Ganapathy GOPALRATHNAM, Jörg HENDLE, John Michael SAUDER, Jeffrey Streetman BOYLES, Anna PUSTILNIK
-
Publication number: 20220348957Abstract: Provided herein are adeno-associated viruses and methods for using same to treat or prevent disorders that affect the inner ear of a subject.Type: ApplicationFiled: January 22, 2021Publication date: November 3, 2022Applicants: The United States of America as represented by the Secretary, Department of health and Human Svcs., The Trustees of the University of PennsylvaniaInventors: Wade W. Chien, Jean Bennett
-
Patent number: 11447541Abstract: Antibodies that bind SARS-CoV Spike protein, SARS-CoV-2 Spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.Type: GrantFiled: June 22, 2021Date of Patent: September 20, 2022Assignees: AbCellera Biologies Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.Inventors: Kathryn Westendorf, Stefanie Zentelis, Krithika Muthuraman, Kevin Jepson, Ester Falconer, John Mascola, Barney Graham, Kizzmekia Corbett, Julie Ledgerwood, Lingshu Wang, Olubukola Abiona, Wei Shi, Wing-pui Kong, Yi Zhang, Bryan Edward Jones, Denisa Foster, Julian Davies, Qing Chai, Christopher Carl Frye, Ganapathy Gopalrathnam, Jörg Hendle, John Michael Sauder, Jeffrey Streetman Boyles, Anna Pustilnik
-
Patent number: 11370828Abstract: Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.Type: GrantFiled: June 22, 2021Date of Patent: June 28, 2022Assignees: AbCellera Biologies Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.Inventors: Kathryn Westendorf, Stefanie Zentelis, Krithika Muthuraman, Kevin Jepson, Ester Falconer, John Mascola, Barney Graham, Kizzmekia Corbett, Julie Ledgerwood, Lingshu Wang, Olubukola Abiona, Wei Shi, Wing-pui Kong, Yi Zhang, Bryan Edward Jones, Denisa Foster, Julian Davies, Qing Chai, Christopher Carl Frye, Ganapathy Gopalrathnam, Jörg Hendle, John Michael Sauder, Jeffrey Streetman Boyles, Anna Pustilnik
-
Publication number: 20220096658Abstract: Provided herein are adeno-associated viruses and methods for using same to treat or prevent disorders that affect the inner ear of a subject.Type: ApplicationFiled: December 20, 2019Publication date: March 31, 2022Applicant: The United States of America, As Represented by The Secretary, Department of Health and Human Svcs.Inventors: Wade W. Chien, Jean Bennett
-
Publication number: 20210388066Abstract: Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.Type: ApplicationFiled: June 22, 2021Publication date: December 16, 2021Applicants: AbCellera Biologics Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.Inventors: Kathryn WESTENDORF, Stefanie ZENTELIS, Krithika MUTHURAMAN, Kevin JEPSON, Ester FALCONER, John MASCOLA, Barney GRAHAM, Kizzmekia CORBETT, Julie LEDGERWOOD, Lingshu WANG, Olubukola ABIONA, Wei SHI, Wing-pui KONG, Yi ZHANG, Bryan Edward JONES, Denisa FOSTER, Julian DAVIES, Qing CHAI, Christopher Carl FRYE, Ganapathy GOPALRATHNAM, Jörg HENDLE, John Michael SAUDER, Jeffrey Streetman BOYLES, Anna PUSTILNIK
-
Publication number: 20210283159Abstract: A pharmaceutical composition containing any one or more of 4?-O-isolvalerylspiramycin I, II and III counters tumorigenesis and reduces or prevents metastasis by inhibiting selenoprotein H to trigger genomic instability and cell-cycle arrest in cancer cells.Type: ApplicationFiled: March 11, 2020Publication date: September 16, 2021Applicants: ASCLEA CORPORATION, THE UNITED STATES OF AMERICA, as represented by the Secretary, Dept, of Health and Human Svcs.Inventors: Enhong JIANG, Zhengping ZHUANG, Jing CUI
-
Patent number: 9744151Abstract: Methods for making trans-(?)-?9-tetrahydrocannabinol and trans-(+)-?9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(?)-?9-tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-?9-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(?)-?9-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(?)-?9-tetrahydrocannabinol based on the total amount of trans-(?)-?9-tetrahydrocannabinol and trans-(+)-?9-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(?)-?9-tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.Type: GrantFiled: March 4, 2016Date of Patent: August 29, 2017Assignee: SVC Pharma LPInventors: Arie L. Gutman, Marina Etinger, Irina Fedotev, Ram Khanolkar, Gennady A. Nisnevich, Boris Pertsikov, Igor Rukhman, Boris Tishin
-
Patent number: 9675581Abstract: Methods for making trans-(?)-?9-tetrahydrocannabinol and trans-(+)-?9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(?)-?9-tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-?9-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(?)-?9-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(?)-?9-tetrahydrocannabinol based on the total amount of trans-(?)-?9-tetrahydrocannabinol and trans-(+)-?9-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(?)-?9-tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.Type: GrantFiled: March 4, 2016Date of Patent: June 13, 2017Assignee: SVC Pharma LPInventors: Arie L. Gutman, Marina Etinger, Irina Fedotev, Ram Khanolkar, Gennady A. Nisnevich, Boris Pertsikov, Igor Rukhman, Boris Tishin
-
Patent number: 9278083Abstract: Methods for making trans-(?)-?9-tetrahydrocannabinoI and trans-(+)-?9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(?)-?9-tetrahydrocannabinoI composition is prepared by allowing a composition comprising (±)-?9-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(?)-?9-tetrahydrocannabinoI composition comprising at least about 99% by weight of trans-(?)-?9-tetrahydrocannabinol based on the total amount of trans-(?)-?9-tetrahydrocannabinol and trans-(+)-?9-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(?)-?9-tetrahydrocannabinoI having a purity of at least about 98% based on the total weight of cannabinoids.Type: GrantFiled: January 13, 2015Date of Patent: March 8, 2016Assignee: SVC Pharma LPInventors: Arie L. Gutman, Marina Etinger, Irina Fedotev, Ram Khanolkar, Gennady A. Nisnevich, Boris Pertsikov, Igor Rukhman, Boris Tishin
-
Publication number: 20140249346Abstract: The process for stabilizing wastes generally comprises blending spent or virgin fullers earth with a hazardous or non-hazardous sludge, soil or sediment to form a matrix. Next, the matrix is blended with a reagent capable of growing a calcium silicate hydrate or Ettringite mineral. In this manner a more stable, less leachable product is formed.Type: ApplicationFiled: October 30, 2013Publication date: September 4, 2014Applicant: Remedial Construction Svc., L.P.Inventor: Steven R. BIRDWELL
-
Publication number: 20140199360Abstract: Medical devices that are resistant to biofilm development and methods of the manufacture of biofilm resistant medical devices are provided. One or more bacteriophages are tethered to the surface of a medical device or a hydrogen-type coating on the surface of the device by covalent bonding while maintaining bacteriophage infective or lytic activity. The presence of the bacteriophages on a medical device, such as an indwelling medical device, prevents biofilm formation or reduces existing biofilm formation on the surface of the device when in use. These devices address the long felt need for biofilm resistant devices that increase safety and reduce complications normally associated with prior indwelling or other medical devices.Type: ApplicationFiled: June 28, 2012Publication date: July 17, 2014Applicant: CDC/The Govt. of the U.S.A. being rep. by Sec. of the Dept. of Hlth. and Human Svcs., Ctrs. for DisInventors: Rodney Martin Donlan, Susan Marie Lehman, Andres J. Garcia
-
Publication number: 20140114859Abstract: A system for conducting a financial transaction in e-commerce on the internet includes objects prepared by a seller and a buyer. The seller's object includes a clear text header file (advertisement), an encrypted overhead file which contains verification data pertaining to the financial transaction, and an encrypted content file containing the subject matter for sale by the seller. With a purchase solicitation from the buyer, an overhead key can be used by a transaction agency to ensure there is a compliance between the purchase solicitation and the verification data of the overhead (from seller's object). Next a revelation key is provided to give the buyer access to the content when such compliance has been ensured.Type: ApplicationFiled: December 31, 2013Publication date: April 24, 2014Applicant: O'HASTINER SVC. LIMITED LIABILITY COMPANYInventors: Robert BIBLE, JR., Mark Steven BURNETT
-
Patent number: 8639626Abstract: A system for conducting a financial transaction in e-commerce on the internet includes objects prepared by a seller and a buyer. The seller's object includes a clear text header file (advertisement), an encrypted overhead file which contains verification data pertaining to the financial transaction, and an encrypted content file containing the subject matter for sale by the seller. With a purchase solicitation from the buyer, an overhead key can be used by a transaction agency to ensure there is a compliance between the purchase solicitation and the verification data of the overhead (from seller's object). Next a revelation key is provided to give the buyer access to the content when such compliance has been ensured.Type: GrantFiled: July 2, 2010Date of Patent: January 28, 2014Assignee: O'Hastiner SVC. Limited Liability CompanyInventors: Robert Bible, Jr., Mark Steven Burnett
-
Publication number: 20120121504Abstract: The invention relates to antibodies that are reactive to the cell surface of CD19+ B cells, including B-cell chronic lymphocytic leukemia (B-CLL) cells, and compositions and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with CD19+ B cells, such as B-CLL.Type: ApplicationFiled: May 12, 2010Publication date: May 17, 2012Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Svcs.Inventors: Christoph Rader, Sivasubramanian Baskar, Michael R. Bishop, Ivan Samija, Jessica M. Suschak
-
Publication number: 20110190295Abstract: Derivatives and analogs of inhibitors of receptor tyrosine kinase c-Met, pharmaceutical compositions containing derivatives and analogs of c-Met inhibitors are provided. Methods of making derivatives and analogs of c-Met inhibitors and methods of use thereof are provided.Type: ApplicationFiled: March 31, 2009Publication date: August 4, 2011Applicant: The Govt of the U.S.A., as rep.by the Sec.Dept of Hlth. and Human Svcs., Natl Institutes of HealthInventors: Donald P. Bottaro, Megan Peach, Marc Nicklaus, Terrence Burke, JR., Gagani Athauda, Sarah Choyke, Alessio Giubellino, Nelly Tan, Zhen-Dan Shi
-
Publication number: 20060009379Abstract: An isolated nucleostemin polypeptide is disclosed herein. The nucleostemin polypeptide includes an amino acid sequence at least 85% identical to SEQ ID NO: 2. In several examples, the polypeptide regulates cell differentiation, cell proliferation, or both. Nucleic acids encoding these polypeptides, vectors including the nucleic acids, and host cells transfected with these nucleic acids are also disclosed. Methods for inducing differentiation, inhibiting proliferation, and inducing senescence of a cell by altering the level of a nucleostemin polypeptide including an amino acid sequence at least 80% identical to SEQ ID NO: 2 are also disclosed. Methods for screening for agents that affect proliferation, differentiation, or senescence of cells are also disclosed.Type: ApplicationFiled: October 1, 2003Publication date: January 12, 2006Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICAN AS REPRESENTED BY THE DEPT. OF HEALTH AND HUMAN SVCInventors: Robert Tsai, Ronald McKay
-
Patent number: 6845828Abstract: A thin layer of carbide containing an ultra-hard component, such as diamond, is applied to a formed compact for a drilling tool. The compact is then subjected to a high-temperature, high-pressure process to bond it to the added layer. This process allows the use of an underlying substrate which has a lower binder content than previously possible. The compact provides superior cutting ability, as even if the diamond-enhanced layer wears through, the carbide can provide enhanced hardness.Type: GrantFiled: August 3, 2001Date of Patent: January 25, 2005Assignee: Halliburton Energy Svcs Inc.Inventor: James E. Boyce